too quiet maybe for a very good reason as stated in their 10-Q, if they are working on a sale to Teva. Dr. Barer is well respected in the industry and as chairman for both companies, he will know how to bring some value back to investors. What is known is that the polymer delivery system has a big future in medicine and Teva wants it, which is why they recently updated their patent to include polymers in their successful drug.
"The Company is in the process of performing analyses of the cumulative unblinded data from the NEWTON 2 study to better understand the basis for this outcome. On April 30, 2018, the Company announced that it is currently exploring strategic alternatives, which may include, without limitation, an acquisition of another company, acquisitions or in-licensing of products or product candidates, technologies or other assets, the sale of all or substantially all of the assets of the Company, a sale of stock, a strategic merger or other business combination transaction or other transaction between the Company and a third party."
